A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and tolerability of
abemaciclib when given in combination with hormone therapy in Indian women with advanced
breast cancer. Participants must have hormone receptor positive (HR+), human epidermal growth
factor receptor 2 negative (HER2-) breast cancer and must live in India. For each
participant, the study could last up to eight months and may include up to eight visits to
the study center.